Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
暂无分享,去创建一个
V. de Lédinghen | J. Vaillant | T. Poynard | V. Ratziu | M. Munteanu | F. Charlotte | J. Vergniol | C. Stanciu | A. Trifan | J. Zarski | Julie France | G. Lenaour
[1] Y. Ngo,et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. , 2012, Journal of hepatology.
[2] A. Burroughs,et al. Non-invasive assessment of liver fibrosis , 2012, Annals of gastroenterology.
[3] Y. Ngo,et al. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] Julien Vergniol,et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. , 2012, Journal of hepatology.
[5] V. de Lédinghen,et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive , 2012, Hepatology.
[6] V. de Lédinghen,et al. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. , 2011, Clinics and research in hepatology and gastroenterology.
[7] T. Poynard,et al. The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test , 2011, The American Journal of Gastroenterology.
[8] Y. Ngo,et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. , 2011, Gastroenterology & hepatology.
[9] Julien Vergniol,et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. , 2011, Gastroenterology.
[10] J. Talwalkar,et al. Noninvasive assessment of liver fibrosis , 2011, Hepatology.
[11] Y. Ngo,et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age , 2011, BMC gastroenterology.
[12] T. Poynard. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. , 2011, Journal of hepatology.
[13] P. Crotty,et al. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[14] Laurent Castera,et al. Non-invasive assessment of liver fibrosis: are we ready? , 2010, The Lancet.
[15] V. de Lédinghen,et al. Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.
[16] V. de Lédinghen,et al. The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[17] Mihai Voiculescu,et al. SAFE biopsy: A validated method for large‐scale staging of liver fibrosis in chronic hepatitis C , 2009, Hepatology.
[18] Gérard Forzy,et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C , 2009, Hepatology.
[19] D. Thabut,et al. Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers , 2008, PloS one.
[20] F. Carrat,et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.
[21] Eva Herrmann,et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.
[22] P. Bossuyt,et al. Evaluation of diagnostic tests when there is no gold standard. A review of methods. , 2007, Health technology assessment.
[23] P Tappenden,et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.
[24] Paul Calès,et al. Sources of variability in histological scoring of chronic viral hepatitis , 2005, Hepatology.
[25] V. de Lédinghen,et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.
[26] V. Paradis,et al. Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.
[27] Xiao-Hua Zhou,et al. Statistical Methods in Diagnostic Medicine , 2002 .
[28] A. Hadgu,et al. A biomedical application of latent class models with random effects , 2002 .
[29] M. Tan,et al. Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. , 1996, Biometrics.
[30] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[31] V. de Lédinghen,et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. , 2012, Journal of hepatology.
[32] S. Bertrais,et al. A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C , 2011, The American Journal of Gastroenterology.
[33] Bryan Lau,et al. Exceeding the limits of liver histology markers. , 2009, Journal of hepatology.
[34] Y. Ngo,et al. Open Access Research Article Prevalence of Liver Fibrosis and Risk Factors in a General Population Using Non-invasive Biomarkers (fibrotest) , 2022 .